TYLENOL WITH CODEINE NO. 3 - TAB TABLET

देश: कनाडा

भाषा: अंग्रेज़ी

स्रोत: Health Canada

इसे खरीदें

सक्रिय संघटक:

ACETAMINOPHEN; CODEINE PHOSPHATE; CAFFEINE

थमां उपलब्ध:

JANSSEN INC

ए.टी.सी कोड:

N02AJ06

INN (इंटरनेशनल नाम):

CODEINE AND PARACETAMOL

डोज़:

300MG; 30MG; 15MG

फार्मास्यूटिकल फॉर्म:

TABLET

रचना:

ACETAMINOPHEN 300MG; CODEINE PHOSPHATE 30MG; CAFFEINE 15MG

प्रशासन का मार्ग:

ORAL

पैकेज में यूनिट:

500

प्रिस्क्रिप्शन प्रकार:

Narcotic (CDSA I)

चिकित्सीय क्षेत्र:

OPIATE AGONISTS

उत्पाद समीक्षा:

Active ingredient group (AIG) number: 0311391005; AHFS:

प्राधिकरण का दर्जा:

CANCELLED POST MARKET

प्राधिकरण की तारीख:

2020-09-25

उत्पाद विशेषताएं

                                _242770 APM.docx _
_EDMS-RIM-101028v6.0 _
_Page 1 of 39 _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
N
TYLENOL
® WITH CODEINE NO. 2
acetaminophen, caffeine and codeine phosphate tablets
300 mg acetaminophen, 15 mg caffeine and 15 mg codeine phosphate
tablets
N
TYLENOL
® WITH CODEINE NO. 3
acetaminophen, caffeine and codeine phosphate tablets
300 mg acetaminophen, 15 mg caffeine and 30 mg codeine phosphate
tablets
Analgesic-Antipyretic
Janssen Inc.
200 Whitehall Drive
Markham, Ontario
L3R 0T5
www.janssen.com/canada
Date of Revision:
September 17, 2020
SUBMISSION CONTROL NO: 242770
All trademarks used under license.
© 2020 Janssen Inc.
_242770 APM.docx _
_EDMS-RIM-101028v6.0 _
_Page 2 of 39 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND PRECAUTIONS
..................................................................................5
ADVERSE REACTIONS
..................................................................................................15
DRUG INTERACTIONS
..................................................................................................17
DOSAGE AND ADMINISTRATION
..............................................................................18
OVERDOSAGE
................................................................................................................21
ACTION AND CLINICAL PHARMACOLOGY
............................................................24
STORAGE AND STABILITY
..........................................................................................26
SPECIAL HANDLING INSTRUCTIONS
.............................................................
                                
                                पूरा दस्तावेज़ पढ़ें
                                
                            

अन्य भाषाओं में दस्तावेज़

उत्पाद विशेषताएं उत्पाद विशेषताएं फ़्रेंच 01-04-2020

इस उत्पाद से संबंधित अलर्ट देखें

दस्तावेज़ इतिहास देखें